These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Høiby N; Krogh Johansen H; Moser C; Song Z; Ciofu O; Kharazmi A Microbes Infect; 2001 Jan; 3(1):23-35. PubMed ID: 11226851 [TBL] [Abstract][Full Text] [Related]
44. Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung. Diaz Caballero J; Clark ST; Coburn B; Zhang Y; Wang PW; Donaldson SL; Tullis DE; Yau YC; Waters VJ; Hwang DM; Guttman DS mBio; 2015 Sep; 6(5):e00981-15. PubMed ID: 26330513 [TBL] [Abstract][Full Text] [Related]
45. CFTR and pseudomonas infections in cystic fibrosis. Tatterson LE; Poschet JF; Firoved A; Skidmore J; Deretic V Front Biosci; 2001 Aug; 6():D890-7. PubMed ID: 11487480 [TBL] [Abstract][Full Text] [Related]
46. Biofilm formation by the small colony variant phenotype of Pseudomonas aeruginosa. Häussler S Environ Microbiol; 2004 Jun; 6(6):546-51. PubMed ID: 15142242 [TBL] [Abstract][Full Text] [Related]
47. Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm. Anand R; Moss RB; Sass G; Banaei N; Clemons KV; Martinez M; Stevens DA Mycopathologia; 2018 Feb; 183(1):263-272. PubMed ID: 28785939 [TBL] [Abstract][Full Text] [Related]
48. Psl Produced by Mucoid Jones CJ; Wozniak DJ mBio; 2017 Jun; 8(3):. PubMed ID: 28634241 [TBL] [Abstract][Full Text] [Related]
49. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Ramsey DM; Wozniak DJ Mol Microbiol; 2005 Apr; 56(2):309-22. PubMed ID: 15813726 [TBL] [Abstract][Full Text] [Related]
50. Differential adaptability between reference strains and clinical isolates of Del Mar Cendra M; Torrents E Virulence; 2020 Dec; 11(1):862-876. PubMed ID: 32697923 [TBL] [Abstract][Full Text] [Related]
52. How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis. Pier GB; Grout M; Zaidi TS; Goldberg JB Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 2):S175-82. PubMed ID: 8876538 [TBL] [Abstract][Full Text] [Related]
56. Mathematical modelling of Pseudomonas aeruginosa biofilm growth and treatment in the cystic fibrosis lung. Miller JK; Brantner JS; Clemons C; Kreider KL; Milsted A; Wilber P; Yun YH; Youngs WJ; Young G; Badawy HT; Milsted A; Clemons C; Kreider KL; Wilber P; Young G; Yun YH; Wagers PO; Youngs WJ Math Med Biol; 2014 Jun; 31(2):179-204. PubMed ID: 23518337 [TBL] [Abstract][Full Text] [Related]
57. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. McCaughey G; McKevitt M; Elborn JS; Tunney MM J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067 [TBL] [Abstract][Full Text] [Related]
58. Pseudomonas aeruginosa attachment and biofilm development in dynamic environments. Ramsey MM; Whiteley M Mol Microbiol; 2004 Aug; 53(4):1075-87. PubMed ID: 15306012 [TBL] [Abstract][Full Text] [Related]
59. Effects of ginseng on Pseudomonas aeruginosa motility and biofilm formation. Wu H; Lee B; Yang L; Wang H; Givskov M; Molin S; Høiby N; Song Z FEMS Immunol Med Microbiol; 2011 Jun; 62(1):49-56. PubMed ID: 21303421 [TBL] [Abstract][Full Text] [Related]
60. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation. Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]